Advanced RNA Delivery Systems for Enhanced Immune Responses
Legal Citation
Summary of the Inventive Concept
The invention presents a next-generation RNA delivery system that leverages self-amplifying mRNA, synthetic lipid bilayers, and targeted delivery to antigen-presenting cells to induce robust and systemic immune responses.
Background and Problem Solved
The original patent introduced a non-viral delivery of RNA for immunization using liposomes and mRNA molecules. However, the technology had limitations in terms of targeted delivery, immune response, and scalability. The new inventive concept addresses these limitations by introducing self-amplifying mRNA, synthetic lipid bilayers, and targeted delivery to antigen-presenting cells, enabling more efficient and effective immune responses.
Detailed Description of the Inventive Concept
The advanced RNA delivery system comprises RNA replicons that self-amplify and express an immunogen, encapsulated in a nanoparticle featuring a synthetic lipid bilayer. This design enables targeted delivery to antigen-presenting cells, enhancing the immune response. The system can be further optimized by incorporating toll-like receptor agonists to amplify the immune response. The inventive concept also encompasses vaccine compositions combining multiple RNA replicons that self-amplify and express different immunogens, providing a robust and adaptive immune response.
Novelty and Inventive Step
The new inventive concept introduces the use of self-amplifying mRNA, synthetic lipid bilayers, and targeted delivery to antigen-presenting cells, which significantly improves the efficiency and effectiveness of RNA delivery for immunization. These advancements provide a paradigm shift in the field, making the original inventive concept obsolete.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different types of nanoparticles, varying the composition of the synthetic lipid bilayer, or incorporating additional immune stimulants. Variations could also involve adapting the system for different immunogens or disease targets, such as cancer or infectious diseases.
Potential Commercial Applications and Market
The advanced RNA delivery system has significant commercial potential in the vaccine and immunotherapy markets, offering a more efficient and effective approach to inducing immune responses. The technology could be applied to various disease areas, including infectious diseases, cancer, and autoimmune disorders, providing a substantial market opportunity.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Nucleic acid delivery systems, specifically RNA-based immunization technologies, requiring expertise in molecular biology, immunology, and nanoparticle engineering with advanced knowledge of RNA modification, delivery mechanisms, and immune response optimization
Person of Ordinary Skill (PHOSITA) Profile
A researcher with a PhD in molecular biology or bioengineering, experienced in vaccine development, RNA modification techniques, and nanoparticle design, familiar with current immunization strategies and emerging RNA delivery technologies
Obviousness Rationale
A PHOSITA would recognize that the PTD's self-amplifying mRNA and targeted delivery approach represents a predictable extension of the source patent's RNA delivery framework. The incorporation of synthetic lipid bilayers and targeted antigen-presenting cell delivery are logical technological progressions within the established RNA immunization domain. The variations demonstrate incremental improvements using known techniques and design strategies commonly employed in RNA delivery research.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,562 |
|---|---|
| Title | Delivery of RNA to trigger multiple immune pathways |
| Assignee(s) | GlaxoSmith Kline Biologicals S.A. |